Clinical Trial Details
| Trial ID: | L0200 |
| Source ID: | NCT03676231 |
| Associated Drug: | SGM-1019 |
| Title: | Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH) |
| Acronym: | -- |
| Status: | Terminated |
| Study Results: | No Results Available |
| Results: | -- |
| Conditions: | Nonalcoholic Steatohepatitis |
| Interventions: | Drug: SGM-1019|Drug: Placebo |
| Outcome Measures: | Evaluation of Safety and Tolerability - Treatment-emergent Adverse Events|Evaluation of Pharmacokinetics - PK|Evaluation of Pharmacodynamics - Labs|Evaluation of Phamacodynamics - MRI |
| Sponsor/Collaborators: | Second Genome |
| Gender: | All |
| Age: | 18 Years to 75 Years ?? (Adult, Older Adult) |
| Phases: | Phase 2 |
| Enrollment: | 9 |
| Study Type: | Interventional |
| Study Designs: | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment |
| Start Date: | January 18, 2019 |
| Completion Date: | May 1, 2019 |
| Results First Posted: | -- |
| Last Update Posted: | July 11, 2019 |
| Locations: | Second Genome Clinical Site 405, Chandler, Arizona, United States|Second Genome Clinical Site 406, Tucson, Arizona, United States|Second Genome Clinical Site 403, Panorama City, California, United States|Second Genome Clinical Site 409, Lakewood Ranch, Florida, United States|Second Genome Clinical Site 410, Flowood, Mississippi, United States|Second Genome Clinical Site 404, Kansas City, Missouri, United States|Second Genome Clinical Site 408, Fayetteville, North Carolina, United States|Second Genome Clinical Site 407, Clarksville, Tennessee, United States|Second Genome Clinical Site 402, Austin, Texas, United States|Second Genome Clinical Site 401, San Antonio, Texas, United States |
| URL: | https://ClinicalTrials.gov/show/NCT03676231 |
